Factors Influencing Improved Survival in Systemic Sclerosis-Associated PAH
Pulmonary arterial hypertension with systemic sclerosis associated-survival improved over time among patients aged 70 years or younger, but not among the elderly.
Pulmonary Hypertension
Cardiac MRI Could Be Useful in Pulmonary Arterial Hypertension Risk Stratification
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
NIV and CPAP Similarly Improve LV Dysfunction in Obesity Hypoventilation Syndrome With OSA
Treatment with noninvasive ventilation and continuous positive airway pressure provided similar improvements in pulmonary hypertension and left ventricular diastolic dysfunction in obesity hypoventilation syndrome and concomitant severe obstructive sleep apnea.
Pulmonary Hypertension After Bone Marrow Transplant in Children Is Underestimated
Pulmonary hypertension is severe complication of hematopoietic stem cell transplantation in children that is often underestimated.
Cardiopulmonary Exercise Testing Plus Screening Algorithm Useful in SSc-Related PAH
Researchers evaluated whether cardiopulmonary exercise testing could improve the performance of the DETECT screening approach in systemic sclerosis-related pulmonary arterial hypertension.
Cardiac MRI Metrics Help Stratify Mortality Risk in Pulmonary Arterial Hypertension
In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
Rapid Iloprost Inhalation Improves Pulmonary Vascular Resistance in PAH
This study assessed improvement in pulmonary vascular resistance and cardiac index in patients with pulmonary arterial hypertension who rapidly inhale iloprost 2.5 ug via the Breelib™ nebulizer.
Thinking Outside the Lungs: Extrapulmonary Manifestations in PAH
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
Treprostinil Approved to Delay Disease Progression in PAH
The FDA has approved the supplemental NDA for Orenitram extended-release tablets for the treatment of PAH to delay disease progression, in addition to improving exercise capacity.
Next post in Pulmonary Hypertension
